Future Fund LLC Purchases 179 Shares of argenex SE $ARGX

Future Fund LLC increased its position in argenex SE (NASDAQ:ARGX) by 24.3% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 915 shares of the company’s stock after purchasing an additional 179 shares during the quarter. Future Fund LLC’s holdings in argenex were worth $504,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. WPG Advisers LLC bought a new position in shares of argenex during the 1st quarter worth about $37,000. Brooklyn Investment Group raised its position in argenex by 102.7% in the first quarter. Brooklyn Investment Group now owns 75 shares of the company’s stock worth $44,000 after purchasing an additional 38 shares in the last quarter. Banque Transatlantique SA bought a new position in argenex during the first quarter worth about $62,000. Geneos Wealth Management Inc. boosted its holdings in argenex by 550.0% during the first quarter. Geneos Wealth Management Inc. now owns 117 shares of the company’s stock valued at $69,000 after purchasing an additional 99 shares in the last quarter. Finally, Raiffeisen Bank International AG acquired a new stake in argenex during the first quarter valued at approximately $76,000. Institutional investors own 60.32% of the company’s stock.

argenex Stock Up 0.4%

Shares of argenex stock opened at $854.65 on Monday. The business has a fifty day simple moving average of $782.86 and a 200 day simple moving average of $663.39. The stock has a market cap of $52.62 billion, a PE ratio of 36.70, a price-to-earnings-growth ratio of 0.89 and a beta of 0.45. argenex SE has a 12 month low of $510.05 and a 12 month high of $857.48.

argenex (NASDAQ:ARGX) last posted its earnings results on Thursday, October 30th. The company reported $4.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.37 by $0.03. The company had revenue of $1.12 billion during the quarter, compared to analyst estimates of $1.07 billion. argenex had a return on equity of 29.78% and a net margin of 41.58%. Analysts expect that argenex SE will post 3.13 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently commented on ARGX. Evercore ISI raised their target price on argenex from $775.00 to $910.00 and gave the stock an “outperform” rating in a research report on Friday, October 31st. JPMorgan Chase & Co. lifted their price objective on argenex from $830.00 to $925.00 and gave the company an “overweight” rating in a report on Friday. Morgan Stanley increased their target price on shares of argenex from $766.00 to $1,040.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 1st. Truist Financial upped their price objective on shares of argenex from $700.00 to $918.00 and gave the stock a “buy” rating in a research note on Monday, September 15th. Finally, Stifel Nicolaus set a $882.00 target price on shares of argenex in a research note on Thursday, September 18th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $869.68.

argenex Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.